Indiana 2023 Regular Session

Indiana Senate Bill SB0214

Introduced
1/10/23  
Refer
1/10/23  
Report Pass
1/19/23  
Engrossed
1/25/23  
Refer
2/7/23  
Report Pass
3/28/23  
Enrolled
4/4/23  
Passed
4/20/23  
Chaptered
4/20/23  

Caption

Standing order for overdose intervention drugs.

Impact

The implementation of SB0214 is expected to significantly impact state health laws by promoting a public health approach toward the opioid crisis. The bill establishes legal protections for individuals who administer overdose intervention drugs in good faith, shielding them from prosecution for drug possession. This change is poised to facilitate a more collaborative effort among healthcare providers, educators, and community members in addressing the epidemic of opioid abuse and enhancing community health outcomes.

Summary

Senate Bill 0214 seeks to address the growing issue of opioid overdoses in Indiana by allowing prescribers to issue standing orders for overdose intervention drugs, such as naloxone, without needing to examine the individual to whom the drug may be administered. The bill establishes specific conditions under which these prescriptions can be made, which includes education about overdose response and referrals to drug addiction treatment programs. By broadening access to overdose intervention drugs, SB0214 aims to empower individuals in preventing opioid-related fatalities and promoting immediate help in overdose situations.

Sentiment

The general sentiment surrounding SB0214 has been largely supportive, with many lawmakers and health advocates recognizing the necessity of such measures in the face of increasing overdose rates. Public health organizations and advocacy groups have voiced approval, highlighting the importance of reducing barriers to accessing life-saving medications. However, there are concerns among opponents regarding the potential for misuse and the adequacy of training provided to individuals administering such drugs, reflecting a cautious approach to the implementation of the bill's provisions.

Contention

A notable point of contention regarding SB0214 involves the balance between accessibility and safety. While many support the intent to save lives through increased access to naloxone, critics have raised questions about whether the necessary educational components and protocols will be adequately put in place to ensure safe usage among laypeople. Additionally, the bill's provisions regarding law enforcement's non-intervention in the event of good faith actions may stir debate regarding the broader implications for drug policy enforcement in the state.

Companion Bills

No companion bills found.

Previously Filed As

IN HB411

Maryland Department of Health - Reports on Standing Orders and Opioid Overdose Reversal Drugs

IN SB408

Maryland Department of Health - Reports on Standing Orders and Opioid Overdose Reversal Drugs

IN A201

Authorizes first responders to obtain, administer, and dispense opioid antidotes, with immunity, pursuant to Statewide standing order issued by State health official; makes clarifying changes to "Overdose Prevention Act."

IN H0222

An act relating to reducing overdoses

IN HB05053

An Act Concerning Opioids And Access To Overdose Reversal Drugs.

IN HB572

Public Health - Opioid Overdose Reversal Drugs

IN SB793

Public Health - Opioid Overdose Reversal Drugs

IN SB394

Statewide Targeted Overdose Prevention (STOP) Act of 2022

IN HB3375

STOP Fentanyl Overdoses Act of 2023 Support, Treatment, and Overdoses Prevention of Fentanyl Overdoses Act of 2023

IN HB3070

Relating to standing orders for short-acting opioid antagonists; prescribing an effective date.

Similar Bills

CA SB172

Health care coverage: fertility preservation.

IN SB0418

Emergency medical assistance.

CA SB805

Health care coverage: pervasive developmental disorders or autism.

CA SB562

Health care coverage: pervasive developmental disorders or autism.

CA SB399

Health care coverage: pervasive developmental disorder or autism.

CA AB2449

Health care coverage: qualified autism service providers.

CA AB1074

Health care coverage: pervasive developmental disorder or autism.

AZ SB1590

Mental health; autism; insurance coverage